The anticipated size of the direct-to-consumer genetic testing market in 2022 was USD 1,485.1 million and is estimated to be USD 1,645.5 million in 2023. direct-to-consumer (DTC) genetic testing has become a rising popularity in recent years, because of the advancements in technology that have made genealogy testing more available and economical. Future Market Insights has mentioned in its reports that the direct-to-consumer genetic testing market will expand at a CAGR of 11.40% between 2023 and 2033, totaling around USD 4,843.4 million by 2033.
Direct-to-consumer genetic testing is an emerging service where various aspects of an individual such as disease complications, health, and similar other traits are provided. Customers are directly marketed to genetic tests via broadcast, newspaper ads, or online databases.
Customers need to submit a DNA sample to the company and obtain results via a secure platform or in a written format. Direct-to-consumer genetic testing enables users to get access to their hereditary or genetic information without seeking help from a medical care provider or health insurance company. It is also known as home DNA testing, which delivers insights into the ancestry and other biological aspects of an individual.
| Attributes | Details |
|---|---|
| Projected Forecast Value (2022) | USD 1,485.1 million |
| Projected Forecast Value (2023) | USD 1,645.5 million |
| Projected Forecast Value (2033) | USD 4,843.4 million |
| Growth rate | 11.4% CAGR |
| Forecast period | 2023 to 2033 |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The global direct-to-consumer genetic testing (DTC-GT) market grew at a CAGR of 9.8% between 2017 and 2022. Growth forecasts remain optimistic, with the market predicted to exhibit a CAGR of 11.4% between 2023 and 2033.
Demand for direct-to-consumer genetic testing will continue to grow at a rapid pace in the forthcoming years owing to their positive impact on human health in terms of safety, easy availability, and adaptability. Growing public awareness about safety and self-curiosity to know oneself better is also likely to drive the market.
Increasing awareness regarding the importance of genetic variations in a broad array of phenotypes that involves different ailments is set to aid growth. Results of these tests showcase whether an individual has a genetic tendency to a specific disease or phenotype of concern, which can be diagnosed at the earliest to initiate efficient disease management.
First sequencing of the human genome, advancements in genome sequencing technology have enabled rapid growth in the field of genomics research. It has further led direct-to-consumer genetic testing to evolve into a new service. The global direct-to-consumer genetic testing market has influenced many people since these tests provide valid information regarding several health risks, personal traits, and overall wellness. The rapid shift of people from clinical laboratories to DTC-GT is another crucial factor that is anticipated to drive the market in the forecast period.
Usage of Genetic Marketers for Affirming the Existence of Kinship Relationships
The use of genetic markers to affirm the existence of kinship relationships between individuals is a relatively simple task that is routinely carried out in forensic laboratories or by using publicly available tests. Introduction of microarray genetic analysis platforms with hundreds of thousands of SNPs will promote the implementation of advanced algorithms to openly test for more secluded genealogical relationships among individuals.
Such personal data is already used in genetic tests, as well as with recently designed statistical methods from evolutionary biology. It is capable of providing a thorough assessment of ancestry and admixture. During the evaluation period, these factors are expected to provide lucrative opportunities for key players in the global direct-to-consumer genetic testing market.
Harmful Genetic Disorders and Chemicals Affecting DNA Arises
Direct-to-consumer genetic testing plays an important role in the healthcare sector. Even though it has superior qualities, it does come along with a few drawbacks. Direct-to-consumer genetic testing may provide a constrained snapshot of a patient's health. Genetic factors that could lead to disorders like cystic fibrosis or Huntington's disease, as well as environmental factors such as harmful chemicals affecting DNA or exposure to ultraviolet rays are not considered for genetic testing.
When people make critical decisions about disease treatment and prevention depending on their test results, the issue occurs when certain ailments are ignored until they start to alter their health. Unforeseen facts about one's wellness, family dynamics, or ancestry can also be distressing or disconcerting. Enough scientific evidence is not provided to corroborate a specific genetic variant to a particular disease or functionality. Testing companies use their customers' genetic information illegally or if the data is stolen, genetic privacy may be compromised.
Presence of Various Home DNA Testing Kit Manufacturers to Boost Growth
North America holds a major portion of the market with a value share of 48.2% whereas the United States holds a direct-to-consumer genetic testing market share of about 42.9% as it is expected to continue to dominate the market in North America throughout the forecast period.
United States of America is one of the dominant and most competitive markets for direct-to-consumer genetic testing in the world. Presence of a large number of manufacturers is expected to result in the production of relatively low-cost units, which would spur the market.
Implementation of stringent norms by regulatory bodies such as the FDA to follow best practices and report information about adverse events associated with these test kits is set to aid growth in the country.
International Companies to Help Provide Genetic Information to Customers
Within Asia Pacific, Japan is said to hold an important part of the market with a value share of 6.3% whereas China market is said to grow at a CAGR of 12.7% in East Asia.
Although only a tiny proportion of the population in India uses genetic screening services growing at a CAGR of 15.3%, demand from customers is rising exponentially. On account of this, many international companies are expected to enter the Asia Pacific’s direct-to-consumer genetic testing market and aim to provide cost-effective services where Australia grows at a CAGR of 8.9%
Ongoing Development of Genome Sequencing Technology to Push Sales
Germany is set to exhibit a CAGR of nearly 7.1% in Europe where it holds 32.7% of the market share in the direct-to-consumer genetic testing market during the forecast period whereas the United Kingdom grows at a CAGR of 11.8%. Increasing awareness of health-influencing genetic factors is expected to grow steadily, thereby pushing the German market.
Breakthroughs in genetic technology, largely defined by cost-effective and more efficient genetic analysis are set to increase at a fast pace. Rising genomic awareness owing to the outcome of genome-wide association studies (GWAS) is expected to aid growth.
GWAS enables a better understanding of genotype-phenotype comparisons and provides additional data on the risks of having genetic diseases. Spurred by the aforementioned factors, the market is likely to grow in Germany.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Ancestry Tests to Exhibit High Growth with Urgent Need to Know Genetic Information
The ancestry tests segment exhibited high growth at a CAGR of 10.9%, with a projected share of about 38.2% in the global market in the same year. Ancestry tests provide better results about an individual’s hereditary information.
Increasing interest of people in knowing about their family tree and ancestors is projected to drive sales of ancestry tests in the future. High demand for cheek swabs or saliva-based DNA test kits in developed regions such as Europe and North America would foster the segment.
Medical Care Providers Are Adopting Single Nucleotide Polymorphism Chips
The single nucleotide polymorphism chips segment held a market share of around 64.5% and is expected to showcase gradual growth over the forecast period. The ability of single nucleotide polymorphism chips to work well on degraded DNA is anticipated to drive the segment.
Single nucleotide polymorphism chips have lower mutation rates, as compared to short tandem repeats (STRs) as it is thus capable of enabling kinship testing and this property would foster the segment in the upcoming decade.
Saliva Samples Be Highly Preferred for Genetic Testing
The saliva segment held a direct-to-consumer genetic testing market share of 67.0%. Saliva samples are cost-effective, pain-free, and user-friendly.
Blood sampling is considered to be a gold standard for sample collection, the participation rate is less compared to saliva samples as this factor is projected to create new opportunities for growth during the forecast period.
Retail Sales to Surge in the Genetic Testing Market
Retail sales segment held the highest direct-to-consumer genetic testing market share of nearly 79.5%. Easy availability of DTC-GT without the involvement of any healthcare professional is propelling sales through retail channels.
Some of the prominent players in the global market are-
Some of the recent industry developments in the global direct-to-consumer genetic testing market are:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 11.40% from 2023 to 2033 |
| Market value in 2023 | USD 1,645.5 million |
| Market value in 2033 | USD 4,843.4 million |
| Base Year for Estimation | 2022 |
| Historical Data | 2017 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | USD million for Value and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Product, Technology, Sample, Sales Channel, Region |
| Regions Covered | North America; Latin America; Western Europe; Eastern Europe; South Asia and Pacific; East Asia; Middle East & Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, Poland, Russia, Czech Republic, Romania, India, Bangladesh, Australia, New Zealand, China, Japan, South Korea, GCC Countries, South Africa, Israel |
| Key Companies Profiled | 23andMe; Ancestry DNA; Color Genomics, Inc.; Genetic Technology (EasyDNA); Full Genomes Corporation, Inc.; Helix OpCo LLC; IDENTIGENE, LLC/ DNA Diagnostics Center; Living DNA Ltd; MyHeritage Ltd; Prenetics Limited; Family Tree DNA; Interleukin Genetics/orig3n; Counsyl/Myriad Genetics, Inc.; Veritas Genetics; Fulgent Genomics |
| Customization & Pricing | Available on Request |
The industry in 2023 is valued at USD 1,645.5 million.
The market CAGR through 2033 is 11.40%.
From 2017 to 2022, the market registered a CAGR of 9.8%.
By 2033, the market will reach USD 4,843.4 million.
Harmful genetic disorders and chemicals affecting DNA Arises are restraining market growth.
| Estimated Market Size (2024E) | USD 688.1 million |
|---|---|
| Projected Market Value (2034F) | USD 3,713.1 million |
| Value-based CAGR (2024 to 2034) | 18.4% |
| Expected Base Year Value (2024) | USD 2.81 billion |
|---|---|
| Anticipated Forecast Value (2034) | USD 4.84 billion |
| Estimated Growth (2024 to 2034) | 5.60% CAGR |
| Market Expected Value (2023) | USD 779.4 million |
|---|---|
| Market Forecast Value (2033) | USD 4.5 billion |
| Market Expected CAGR (2023 to 2033) | 19.2% |
Explore In-vitro Diagnostics Devices Insights
View Reports
Direct-to-Consumer Genetic Testing Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
